Bayer says Nexavar fails in breast cancer study

Whatsapp News

FRANKFURT – German drugmaker Bayer said a Phase III of cancer drug Nexavar in patients advanced breast cancer did not meet its primary endpoint of delaying the progression of the .

The , called Resilience, evaluated Nexavar in combination chemotherapeutic agent capecitabine, in HER2-negative breast cancer.


Oral drug Nexavar, which Bayer is developing jointly Amgen, is approved for against certain types of liver, kidney and thyroid cancer.

details are expected be presented at an upcoming scientific . (Reuters)